|
|
 |
|
|
<< Back
FDA Approves Gilead AIDS Drug for Hepatitis B
|
|
Abstract
|
| On Monday, Gilead Sciences Inc. announced that the Food and Drug Administration has approved its HIV drug Viread (tenofovir) as a treatment for hepatitis B. The approval was based on two clinical trials demonstrating that Viread is more effective than Hepsera in fighting liver inflammation and scarring caused by chronic hepatitis B infection, the biotech company said.
Chronic hepatitis B is a major cause of liver cancer, and many of the people who have the infection have not been diagnosed.
Viread is also an approved treatment for chronic hepatitis B in Europe, Turkey, Australia, and New Zealand, Gilead said.
|
|
|
|
|
|
|
|
|
Subjects
|
Federal Government Agencies
Hepatitis B
Legal Issues
Therapeutic Drugs
Treatment
|
|
|
|
|
Disclaimer: NPIN provides this information as a public service only. The views and information provided about the materials, news, funding opportunities, organizations, and conferences do not necessarily state or reflect those of the U.S. Department of Health and Human Services, CDC, or NPIN.
|
|
|
cdcnpin.org News Record #51481
|
|
<< Back
|
|
|
|
